- Home
- / Marinus Pharmaceuticals
Marinus Pharmaceuticals
Stock Price
$0.3
2024-10-29
Market Capitalization
$16 M
2024-10-29
Revenue
$31 M
FY, 2023
Marinus Pharmaceuticals Summary
Company Summary
- Overview
- Marinus Pharmaceuticals is a clinical stage biopharmaceutical company. It is engaged in the development and commercialization of ganaxolone. The Company develops treatments for patients suffering from drug-resistant seizures and neuropsychiatric disorders.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Radnor, PA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
David Czekai, Senior Vice President, Chemistry, Manufacturing & Controls
Alex Aimetti, Vice President, Scientific Affairs
Michael R. Dougherty, Director
LocationsView all
1 location detected
Radnor, PA HQ
United States
100 Matsonford Rd # 500
Marinus Pharmaceuticals Financials
Summary Financials
- Revenue (Q3, 2024)
- $8.5M
- Net income (Q3, 2024)
- ($24.2M)
- Cash (Q3, 2024)
- $42.2M
- EBIT (Q3, 2024)
- ($21.1M)
- Enterprise value
- $43.5M